Prevalence of American Tripanosomiasis in Pregnant Women from a Health Area of Valencia, Spain. 2005-2007

Fundamento: La enfermedad de Chagas es una patología emergente en nuestro medio debido principalmente al incremento de las migraciones. La prevalencia y el difícil manejo terapéutico hacen del Chagas un problema de salud pública creciente. Pretendemos analizar la prevalencia y perfil epidemiológico de mujeres gestantes latinoamericanas atendidas en el área de influencia del Hospital Clínico de Valencia (HCUV) y estimar el riego de transmisión vertical. Métodos: Se estudió a 383 mujeres gestantes asistidas en el HCUV entre febrero de 2005 y julio de 2007. Utilizamos para el cribado la técnica de inmunoprecipitación ID-PaGIA-DiaMed, confirmada mediante Inmunofluorescencia Indirecta (IFI) - Inmunoflour Chagas-Inverness Medical. En hijos de mujeres positivas: Microhematocrito, PCR y detección de anticuerpos IgM por IFI, al nacer, e IgG, a los 6 y 12 meses. Resultados: El 9,7% de las mujeres presentaban anticuerpos específicos del parásito. De ellas el 54,1% eran bolivianas, el 13,5% argentinas y 8,1 % colombianas. 81,1% vivieron en zonas rurales y casas de adobe, el 89,2% tenía antecedentes familiares y el 100% conocían la enfermedad y el vector. La seroconversión en un niño de 8 meses supuso una transmisión vertical del 2,7% y una incidencia en mujeres procedentes de zona endémica del 0,3%. Conclusiones: La prevalencia de enfermedad de Chagas en mujeres gestantes latinoamericanas es elevada y supone un riesgo de transmisión vertical importante que obliga a detectar anticuerpos frente al parásito en los exámenes de salud de este colectivo. En el cribado son factores de riesgo los antecedentes familiares de tripanosomiasis y la residencia previa en hábitat rural.Background: The Chagas disease, an endemic illness in Latin America, is an emerging pathology due mainly to the increment of human migration. Prevalence increase, difficult diagnosis and therapeutic management turn Chagas into an important public health problem. Our objectives are first to analyse the seroprevalence and epidemiologic profile of Latin American pregnant women who were taken charge of in the area of Hospital Clinical University of Valencia (HCUV), and second, to determine the risk of vertical transmission from infected women to their children. Method: 400 Latin American pregnant women were analysed. They were assisted in HCUV from February 2005 to July 2007. The screening technique used was Immunoprecipitation ID-PaGIA_DiaMed, confirmed through Indirect Immunofluorescence (Immunofluor Chagas-Inverness Medical). For newborns whose mothers were seropositive, a microhematocrit and PCR was performed at birth, later IgG detection was performed at 6 and 12 months. Results: 9.3% of pregnant women developed specific antibodies to the parasite. Trypanosomiasis illness in antecedents, living in rural areas and gastrointestinal symptomatology were the most outstanding risk markers among the epidemiological, sociodemographic and clinical variables analysed, especially when women were Bolivians. There was a case of seroconversion in an 8 months child with an incidence of 0.25%. Conclusions: The high proportion of pregnant Latin American women with latent Chagas disease, the epidemiological history and the risk of vertical transmission made advisable to include the detection of parasite antibodies in the health screenings of this group.Enfermerí

Brote nosocomial de sarampión

Desde 2010, España y el resto de la Unión Europea presentan niveles de incidencia de sarampión no observados en las dos últimas décadas. En la Comunidad Valenciana en junio del 2011 se notifica el primer caso de sarampión confirmado correspondiente al brote epidémico iniciado en la ciudad de Valencia. El 15 de agosto se produce la transmisión al personal sanitario iniciándose un brote nosocomial. Se diseñó un estudio longitudinal, anidado en el seguimiento de la situación epidémica, para casos incidentes vinculados al territorio hospitalario. Desde el 26 de junio hasta el cierre del brote nosocomial se produjeron 177 notificaciones de sarampión, que permitieron confirmar 151 casos. Cincuenta casos correspondieron al brote comunitario que dio origen a la situación epidémica; al brote nosocomial, 21 casos. El genotipo obtenido fue Paramixovirus D4. El estado inmunitario frente al sarampión era desconocido en el 52,38%. El personal afectado pertenecía al área de urgencias. La finalización de la situación epidémica fue consecuencia más de la eliminación natural de población susceptible que de medidas activas de protección. En nuestra opinión este brote pone de manifiesto que la extensión a la población general se produjo, en gran parte, como consecuencia del brote nosocomial.Enfermerí

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19 : a multicentre, randomised, double-blind, non-inferiority phase IIb trial

A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study dose-escalation trial. Here, we report the interim results of the Phase IIb HH-2, where the immunogenicity and safety of a heterologous booster with PHH-1V is assessed versus a homologous booster with BNT162b2 at 14, 28 and 98 days after vaccine administration. The HH-2 study is an ongoing multicentre, randomised, active-controlled, double-blind, non-inferiority Phase IIb trial, where participants 18 years or older who had received two doses of BNT162b2 were randomly assigned in a 2:1 ratio to receive a booster dose of vaccine-either heterologous (PHH-1V group) or homologous (BNT162b2 group)-in 10 centres in Spain. Eligible subjects were allocated to treatment stratified by age group (18-64 versus ≥65 years) with approximately 10% of the sample enrolled in the older age group. The primary endpoints were humoral immunogenicity measured by changes in levels of neutralizing antibodies (PBNA) against the ancestral Wuhan-Hu-1 strain after the PHH-1V or the BNT162b2 boost, and the safety and tolerability of PHH-1V as a boost. The secondary endpoints were to compare changes in levels of neutralizing antibodies against different variants of SARS-CoV-2 and the T-cell responses towards the SARS-CoV-2 spike glycoprotein peptides. The exploratory endpoint was to assess the number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster. This study is ongoing and is registered with , . From 15 November 2021, 782 adults were randomly assigned to PHH-1V (n = 522) or BNT162b2 (n = 260) boost vaccine groups. The geometric mean titre (GMT) ratio of neutralizing antibodies on days 14, 28 and 98, shown as BNT162b2 active control versus PHH-1V, was, respectively, 1.68 (p < 0.0001), 1.31 (p = 0.0007) and 0.86 (p = 0.40) for the ancestral Wuhan-Hu-1 strain; 0.62 (p < 0.0001), 0.65 (p < 0.0001) and 0.56 (p = 0.003) for the Beta variant; 1.01 (p = 0.92), 0.88 (p = 0.11) and 0.52 (p = 0.0003) for the Delta variant; and 0.59 (p ≤ 0.0001), 0.66 (p < 0.0001) and 0.57 (p = 0.0028) for the Omicron BA.1 variant. Additionally, PHH-1V as a booster dose induced a significant increase of CD4 + and CD8 + T-cells expressing IFN-γ on day 14. There were 458 participants who experienced at least one adverse event (89.3%) in the PHH-1V and 238 (94.4%) in the BNT162b2 group. The most frequent adverse events were injection site pain (79.7% and 89.3%), fatigue (27.5% and 42.1%) and headache (31.2 and 40.1%) for the PHH-1V and the BNT162b2 groups, respectively. A total of 52 COVID-19 cases occurred from day 14 post-vaccination (10.14%) for the PHH-1V group and 30 (11.90%) for the BNT162b2 group (p = 0.45), and none of the subjects developed severe COVID-19. Our interim results from the Phase IIb HH-2 trial show that PHH-1V as a heterologous booster vaccine, when compared to BNT162b2, although it does not reach a non-inferior neutralizing antibody response against the Wuhan-Hu-1 strain at days 14 and 28 after vaccination, it does so at day 98. PHH-1V as a heterologous booster elicits a superior neutralizing antibody response against the previous circulating Beta and the currently circulating Omicron BA.1 SARS-CoV-2 variants in all time points assessed, and for the Delta variant on day 98 as well. Moreover, the PHH-1V boost also induces a strong and balanced T-cell response. Concerning the safety profile, subjects in the PHH-1V group report significantly fewer adverse events than those in the BNT162b2 group, most of mild intensity, and both vaccine groups present comparable COVID-19 breakthrough cases, none of them severe. HIPRA SCIENTIFIC, S.L.U

Effectiveness of surface coatings containing silver ions in bacterial decontamination in a recovery unit

Abstract Background HAIs remain a frequent complication for hospitalised patients and pose a challenge that must be tackled by our health systems. Methods Quasi-experimental study. In order to determine the antimicrobial effectiveness of surface coating agents containing silver ions (BactiBlock®) the degree of contamination of several surfaces in two ICU wards was compared. The association between application of Bactiblock® and surface contamination was analysed using a relative risk (RR). Multivariate logistic regressions were performed for each product applied and each sampling location to adjust for the RR of the contamination of surfaces treated with Bactiblock® for the independent variables. Results Surface contamination was observed in 31.5% of treated samples and 27.4 of untreated samples. Contamination was equally prominent on bedside Tables (38.7%), bed rails (38.4%) and sinks (38.3%), while the walls showed minimum contamination (2.6%). For beds under isolation protocols, contamination was higher (32.6%) than when no protocol was followed (26.5%) but the difference was not significant (p = 0.148). After stratification for application method and adjusting the multivariate models for period of the study and presence of isolated patients, the risk of contamination after the intervention increased when the coating agent was applied using a spray (OR = 1.79; 95% CI: 1.08-2.95, particularly in a dry and rugged surface such as that of bedside Tables (OR = 2.59; 95% CI: 1.22-5.52); and decreased when the product was applied using a roller on a smooth and continuously cleaned (or wet) Surface (OR = 0.42; 95% CI: 0.19-0.92). Conclusion Coating of hospital surfaces with substances containing silver ions may reduce bacterial growth. However, the effectiveness of the coating agent is affected by application method and environmental conditions and the type and cleanness of the surface

Prevalencia de tripanosomiasis americana en mujeres gestantes de un área de salud. Valencia, 2005-2007.

Fundamento: La enfermedad de Chagas es una patología emergente en nuestro medio debido principalmente al incremento de las migraciones. La prevalencia y el difícil manejo terapéutico hacen del Chagas un problema de salud pública creciente. Pretendemos analizar la prevalencia y perfil epidemiológico de mujeres gestantes latinoamericanas atendidas en el área de influencia del Hospital Clínico de Valencia (HCUV) y estimar el riego de transmisión vertical. Métodos: Se estudió a 383 mujeres gestantes asistidas en el HCUV entre febrero de 2005 y julio de 2007. Utilizamos para el cribado la técnica de inmunoprecipitación ID-PaGIA-DiaMed, confirmada mediante Inmunofluorescencia Indirecta (IFI) - Inmunoflour Chagas-Inverness Medical. En hijos de mujeres positivas: Microhematocrito, PCR y detección de anticuerpos IgM por IFI, al nacer, e IgG, a los 6 y 12 meses. Resultados: El 9,7% de las mujeres presentaban anticuerpos específicos del parásito. De ellas el 54,1% eran bolivianas, el 13,5% argentinas y 8,1 % colombianas. 81,1% vivieron en zonas rurales y casas de adobe, el 89,2% tenía antecedentes familiares y el 100% conocían la enfermedad y el vector. La seroconversión en un niño de 8 meses supuso una transmisión vertical del 2,7% y una incidencia en mujeres procedentes de zona endémica del 0,3%. Conclusiones: La prevalencia de enfermedad de Chagas en mujeres gestantes latinoamericanas es elevada y supone un riesgo de transmisión vertical importante que obliga a detectar anticuerpos frente al parásito en los exámenes de salud de este colectivo. En el cribado son factores de riesgo los antecedentes familiares de tripanosomiasis y la residencia previa en hábitat rural